2023-506094-35-00招募中1 期
A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 77
- 试验地点
- 12
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
GSM-CT
Scientific
Celgene Corp.
研究点 (12)
Loading locations...
相似试验
暂停
1 期
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple MyelomaNCT06232044Alliance for Clinical Trials in Oncology88
招募中
1 期
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaNCT06785415Mayo Clinic37
已完成
4 期
Efficacy and safety of Ivabradine (Coralan) in the treatment of stable angina pectorisCTRI/2010/091/003007Serdia Pharmaceuticals India Pvt Ltd Mumbai300
已完成
1 期
Evaluation of the Feasible dose of Lenalidomide as maintenance therapy after Allogeneic hematopoietic stem cell Transplantation for multiple myelomamultiple myeloma (including plasma cell leukemia)JPRN-UMIN000010470Division of Hematology, Saitama Medical Center, Jichi Medical University9
已完成
2 期
Efficacy and Safety Study of the Ivabradine Hydrochloride Tablets versus Atenolol Tablets in Patients With Chronic Stable Angina Pectoris.Coronary heart diseaseCardiovascular - Coronary heart diseaseACTRN12613000354785Fu Wai Hospital336